Jefferies Maintains Pfizer to Buy with Price Target $40.00

Brokerage firm Jefferies Maintains its rating on Pfizer(NYSE:PFE). In a research note issued to the investors, the brokerage major Lowers the price-target to $40.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Jun 20, 2016.

In a different note, On Jun 14, 2016, Jefferies said it Maintains its rating on Pfizer. In the research note, the firm Raises the price-target to $41.00 per share. The shares have been rated ‘Buy’ by the firm. Berenberg said it Initiates Coverage on Pfizer, according to a research note issued on May 12, 2016. The shares have been rated ‘Hold’ by the firm. On May 9, 2016, Credit Suisse said it Maintains its rating on Pfizer. In the research note, the firm Raises the price-target to $38.00 per share. The shares have been rated ‘Outperform’ by the firm. On May 5, 2016, Leerink Swann said it Maintains its rating on Pfizer. In the research note, the firm Raises the price-target to $34.70 per share. The shares have been rated ‘Market Perform’ by the firm. On May 2, 2016, Leerink Swann said it Maintains its rating on Pfizer. In the research note, the firm Lowers the price-target to $37.00 per share. The shares have been rated ‘Market Perform’ by the firm. On Apr 18, 2016, Goldman Sachs said it Reinstates its rating on Pfizer. The shares have been rated ‘Neutral’ by the firm.

Pfizer (PFE) shares turned negative on Fridays trading session with the shares closing down -0.62 points or -1.79% at a volume of 4,40,00,223. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $34.45. The peak price level was also seen at $34.45 while the days lowest was $33.74. Finally the shares closed at $33.97. The 52-week high of the shares is $36.46 while the 52-week low is $28.25. According to the latest information available, the market cap of the company is $206,023 M.

Pfizer(PFE) last announced its earnings results on May 3, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $13.01B. Analysts had an estimated revenue of $11.96B. Earnings per share were $0.67. Analysts had estimated an EPS of $0.55.

Several Insider Transactions has been reported to the SEC. On May 27, 2016, Frank A Damelio (Executive Vice President) sold 100,000 shares at $34.49 per share price.Also, On May 26, 2016, Loretta V Cangialosi (Sr. Vice President, Controller) sold 86,000 shares at $33.97 per share price.On May 12, 2016, Laurie J Olson (Executive Vice President) sold 4,700 shares at $33.50 per share price, according to the Form-4 filing with the securities and exchange commission.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *